1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Cathepsin

Cathepsin

Cathepsins are protease enzymes, categorized into multiple families. Cathepsins can be serine protease, cysteine protease, or aspartyl protease. There are about 15 classes of cathepsins in humans (Cathepsin A, B, C, D, E, F, G, H, K, L, O, S, V, W, and Z). Cathepsins are active in the low pH milieu of lysosomes and are versatile in their functions. Like other enzymes, they are vital for the normal physiological functions such as digestion, blood coagulation, bone resorption, ion channel activity, innate immunity, complement activation, apoptosis, vesicular trafficking, autophagy, angiogenesis, proliferation, and metastasis, among scores of others.

Numerous pathologies have been attributed to the dysregulated cathepsins, some of which include arthritis, periodontitis, pancreatitis, macular degeneration, muscular dystrophy, atherosclerosis, obesity, stroke, Alzheimer's disease, schizophrenia, tuberculosis, and Ebola.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-18234AR
    Leupeptin hemisulfate (Standard)
    Inhibitor
    Leupeptin (hemisulfate) (Standard) is the analytical standard of Leupeptin (hemisulfate). This product is intended for research and analytical applications. Leupeptin hemisulfate is a broad-spectrum, membrane-permeable protease inhibitor. Leupeptin hemisulfate potently inhibits serine, cysteine and threonine proteases. Leupeptin hemisulfate inhibits Mpro (the main protease of SARS-CoV-2) and also has anti-inflammatory activity[1][2][3].
    Leupeptin hemisulfate (Standard)
  • HY-181741
    PI3K-001
    PI3K-001 is a cathepsin B-responsive prodrug and antifibrotic agent. PI3K-001 undergoes cathepsin B-mediated cleavage of the Val-Ala linker in fibrotic lung lesions to release an active PI3K inhibitor payload, while it remains stable in healthy tissues. PI3K-001 improves collagen deposition, tissue collapse and alveolar injury in fibrotic lung tissues. PI3K-001 is applicable for the research of pulmonary fibrosis.
    PI3K-001
  • HY-163389
    Mpro/Cathepsin L-IN-1
    Inhibitor
    Mpro/Cathepsin L-IN-1 (Compound 4d) is a SARS-CoV-2 Mpro/hCatL inhibitor, with Kis of 5.54 μM and 0.701 μM respectively.
    Mpro/Cathepsin L-IN-1
  • HY-RS03324
    Ctsb Rat Pre-designed siRNA Set A
    Inhibitor

    Ctsb Rat Pre-designed siRNA Set A contains three designed siRNAs for Ctsb gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ctsb Rat Pre-designed siRNA Set A
  • HY-164956
    TB-9
    Inhibitor
    TB-9, a Tasiamide B (HY-N15154) derivative, is a potent cathepsin D, cathepsin E, and BACE1 inhibitor with IC50s of 0.0783 nM, 0.724 nM, and 54.2 nM, respectively.
    TB-9
  • HY-177315
    Cathepsin K-IN-8
    Inhibitor
    Cathepsin K-IN-8 (cxample 6-60) is a cathepsin K inhibitor that can be used for the study of inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.
    Cathepsin K-IN-8
  • HY-P10922
    Cathepsin E substrate e
    Cathepsin E substrate e is a substrate of Cathepsin E. Cathepsin E substrate e was designed in such a way that due to the close proximity of a Mca-donor and a Dnp-acceptor, a near complete intramolecular quenching effect was achieved in its intact state. After the proteolytic cleavage of the hydrophobic motif of the peptide substrate, both Mca and Dnp would be further apart, resulting in bright fluorescence.
    Cathepsin E substrate e
  • HY-181676
    Anti-inflammatory agent 113
    Inhibitor
    Anti-inflammatory agent 113 (compound B5) is a Cathepsin L (CTSL) inhibitor and anti-inflammatory agent with a CTSL IC50 of 5.52 μM. Anti-inflammatory agent 113 suppresses CTSL maturation, attenuates NF-κB and p38 MAPK signaling pathway activation, and binds stably in CTSL’s active site via noncovalent interactions with Asp162, Cys25, and Glu63. Anti-inflammatory agent 113 inhibits pro-inflammatory cytokine (IL-6, IL-8) production, reduces inflammatory cell lung infiltration, and alleviates lung tissue injury. Anti-inflammatory agent 113 can be used for the research of acute lung injury.
    Anti-inflammatory agent 113
  • HY-182614
    BJ-2302
    Inhibitor
    BJ-2302 is a Src kinase inhibitor with an IC50 of 3.23 μM, and inhibits cathepsin S (CTSS) activity.BJ-2302 binds to Src, suppresses PI3K/AKT and Ras/Raf/ERK pathways, and reduces CTSS and MMP-9 expression.BJ-2302 inhibits cancer cell invasion, metastasis, proliferation, and tumor growth.BJ-2302 does not induce cytotoxicity in normal breast epithelial cells.BJ-2302 can be used for the research of breast cancer and triple-negative breast cancer.
    BJ-2302
  • HY-161596
    SmCB1-IN-1
    Inhibitor
    SmCB1-IN-1 (Compound 2h) is an inhibitor for S. mansoni cathepsin B1 (SmCB1) with an Ki of 0.05 μM. SmCB1-IN-1 exhibits selectivity toward human off-target cathepsins (29% and 37% inhibition for CatB and CatL at 20 μM). SmCB1-IN-1 inhibits 68% Schistosoma mansoni at 1 μM.
    SmCB1-IN-1
  • HY-RS03337
    CTSK Human Pre-designed siRNA Set A
    Inhibitor

    CTSK Human Pre-designed siRNA Set A contains three designed siRNAs for CTSK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CTSK Human Pre-designed siRNA Set A
  • HY-155667
    Z-Nle-Lys-Arg-AMC
    Z-Nle-Lys-Arg-AMC is a fluorogenic peptide substrate that specifically monitors cathepsin B activity over a broad pH range.
    Z-Nle-Lys-Arg-AMC
  • HY-172242
    Verducatib
    Inhibitor 98.94%
    Verducatib (BI 1291583) is an orally active inhibitor of cathepsin C (also known as DPP1). Verducatib restores the protease-inhibitor balance by inhibiting the activation of neutrophil serine proteases, thereby alleviating pulmonary inflammation and regulating infection responses. Verducatib significantly reduces the risk (including severe exacerbations) and frequency of acute exacerbations in bronchiectasis (BE). Verducatib also improves lung function and quality of life, and shortens the duration of antibiotic use. The overall incidence of adverse events of Verducatib is comparable to that of placebo, with only slightly more mild-to-moderate cutaneous adverse events observed in the high-dose group, demonstrating promising clinical application potential.
    Verducatib
  • HY-171925
    BI-1124
    Inhibitor
    BI-1124 is a cathepsin S inhibitor that exhibits simulated sufficient ocular pharmacokinetic-pharmacodynamic coverage in rabbit models via topical ocular administration. BI-1124 can be used for the research of age-related dry eye disease.
    BI-1124
  • HY-161244
    FGA145
    Inhibitor
    FGA145 is a dual, selective inhibitor for Mpro and human Cathepsin L, with Kis of 3.71 μM, 9.82 μM and 53 nM, for Mal-Mpro, pET21-Mpro and Cathepsin L, respectively. FGA145 reveals a multitarget effects in the antiviral activity.
    FGA145
  • HY-112111A
    Poly-L-Glutamic acid (MW 100000)
    Substrate
    Poly-L-Glutamic acid (MW 100000) is a synthetic polypeptide with biocompatibility, biodegradability and non-immunogenicity. Poly-L-Glutamic acid is an ideal tumor-targeting polymer carrier. Poly-L-Glutamic acid can be hydrolyzed by cathepsin B during metabolic decomposition.
    Poly-L-Glutamic acid (MW 100000)
  • HY-155611
    Cathepsin C-IN-6
    Inhibitor
    Cathepsin C-IN-6 (compound 2) is a E-64c-hydrazideas based inhibitor of cathepsin C with anti-inflammatory activity. Cathepsin C-IN-6 inhibts activation of neutrophil elastase,exhibits potential efficacy in inflammatory diseases with high neutrophil load (e.g.,chronic obstructive pulmonary disease).
    Cathepsin C-IN-6
  • HY-P4404
    Abz-GIVRAK(Dnp)
    Abz-GIVRAK(Dnp) is the most efficient substrate for cathepsin B and is highly selective for this enzyme among lysosomal cysteine proteases. After Abz-GIVRAK(Dnp) is hydrolyzed, aminoacylbenziminosulfosuccinic acid (Abz-SAS) is released, and dinitrobenzoyl (Dnp) is also released. The product of this hydrolysis reaction, Abz-SAS, is fluorescent under ultraviolet light and can emit a fluorescent signal.
    Abz-GIVRAK(Dnp)
  • HY-120288
    AM4299B
    Inhibitor
    AM4299B is an inhibitor for thiol protease. AM4299B inhibits bovine spleen cathepsin B, human kidney cathepsin L and papain with IC50s of 0.7, 0.5 and 20 μM, respectively. AM4299B can be used in research in osteoporosis, and has potential to be used as an antiparasitic agent.
    AM4299B
  • HY-P5999
    Z-FG-NHO-Bz
    Inhibitor
    Z-FG-NHO-Bz is a selective cathepsin inhibitor.
    Z-FG-NHO-Bz
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.